Efficacy and safety of tetramethylpyrazine phosphate on pulmonary hypertension: study protocol for a randomized controlled study

CURRENT STATUS: ACCEPTED

Jian Wang
State Key Laboratory of respiratory disease
jianwanggzm@163.com
Corresponding Author
ORCiD: 0000-0002-1278-256X

Yuqin Chen
Skate Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Wenjun He
National Institute of Tuberculosis and Respiratory Diseases

Haiping Ouyang
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Chunli Liu
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Cheng Hong
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Tao Wang
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Kai Yang  
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Wenju Lu  
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

DOI:  
10.21203/rs.2.9435/v2

SUBJECT AREAS  
Interdisciplinary Medicine

KEYWORDS  
pulmonary hypertension, tetramethylpyrazine, randomized controlled study
Abstract

Introduction Tetramethylpyrazine (TMP), one of the active ingredients from the traditional Chinese herbal medicine Rhizoma Chuanxiong (Chuanxiong), has been clinically used for the prevention and treatment on cardiovascular diseases. The benefits of TMP are largely attributed to its anti-oxidize and vasodilative activities. However, the efficacy of TMP in the treatment of pulmonary hypertension (PH) is unknown, in this study, we hypothesized that TMP treatment has a therapeutic effect on PH patients.

Background

Pulmonary hypertension (PH) is a serious condition characterized by sustained elevated mean pulmonary arterial pressure over 20 mmHg and progressive right ventricle hypertrophy, leading to cardiac failure and, even death. [1-5]. With improvements in diagnostic techniques, PH is no longer a rare disease. According to the latest epidemiological data, the prevalence of PH is about 1% of the global population. [6] Although understanding of the pathophysiology and pathogenesis of PH has increased, and life quality of patients has improved significantly through the use of targeted drugs, however, combination therapy is more effective than mono-therapy, so it is important to find new drugs to improve efficacy. [7-10] In addition, the use of effective drugs is limited by their high cost, which largely restricts the PH patients from developing countries to afford economic burden of these treatments. Therefore, it is imperative to develop new and affordable medications with strong efficacy and safety profiles.

Given its anti-oxidative, anti-myocardial injury, and vasodilative effects [11-14], tetramethylpyrazine (TMP), a traditional Chinese herbal medicine, is widely used in the treatment of cardiovascular and cerebrovascular diseases [15-18]. The pathogenesis of PH involves oxidative stress, vascular inflammation, and imbalance of intracellular calcium
homeostasis [19-21]. In our previous study, we showed that TMP intervention improves calcium imbalance in pulmonary artery smooth muscle cells (PASMCs) by modulating the expression of TRPC1, TRPC6, Kv1.5, and Kv2.1 in a rat model of PH, potentially through reducing the intracellular free calcium concentration to inhibit the contraction and proliferation of PASMCs and the remodeling of the distal small pulmonary arteries. However, it has not yet been reported whether TMP has a therapeutic effect on PH. We therefore designed a 16-week, randomized, single-blinded, clinically controlled study to examine the efficacy and safety of TMP phosphate for the treatment of PH.

**Methods**

**Study design**

We designed a study protocol for a randomized controlled study. Screening (Visit 0) is undertaken within 3 days prior to enrollment to assess eligibility and collect baseline data. Subjects who entered the primary screening were assessed for lung function, and those meeting all criteria will be randomly assigned (2:1) into TMP treatment group or control group. Both groups received conventional treatment, additionally, the patients in TMP treatment group received 100 mg oral TMP (t.i.d). Patients were followed up at week-4 after randomization (Visit 1), and then followed up every 4 weeks until the end of treatment at 16 weeks. Data collected at Visit 0 included patient characteristics (name, sex, age), medical history, concomitant medications, laboratory and auxiliary examinations, and adverse events. Additionally, at each visit, medical history, medications, cardiac and pulmonary function, and adverse events will be collected. Additional items will be evaluated at Visits 2 and 4. A schedule of assessments is shown in Table 1. A study flow chart is shown in Figure 1.

**Sampling**

Based on the 6-minute walk distance (6MWD) as one of the main efficacy index, it is
assumed that after treatment, the experimental group will be able to walk an average distance of 60 m further than the control group in 6 minutes, the standard deviation is 60 m, $\alpha$ is 0.05, and the efficacy is 90% ($\beta$ is 0.10). Thus, the required sample size is: (see Equation 1 in the Supplementary Files)

where $q_1$ is the proportion of the experimental group, and $q_2$ is the proportion of the control group, $q_1=2/3$, $q_2=1/3$, $N=107$.

Assuming a dropout rate of 11%, the required sample size is approximately 120 participants, comprising 40 patients in the control group and 80 patients in the TMP group.

**Study procedure**

**Eligibility criteria for enrollment**

The selection of participants will be based on the following inclusion and exclusion criteria.

**Inclusion criteria**

1. In accordance with the diagnostic criteria for PH, mean pulmonary arterial pressure measured by right cardiac catheterization above 20 mmHg and pulmonary capillary wedge pressure below 15 mmHg at sea level and pulmonary vascular resistance $>3WU$ in a resting state.

2. Subjects with Type 1 or Type 4 PH classified according to the World Symposium on Pulmonary Hypertension [21] who are in a stable stage (under regular medications without fluctuation in one month), including idiopathic PH, hereditary PH, PH induced by drugs or toxins, PH associated with connective tissue diseases or congenital heart diseases (with no surgery/intervention within the previous 6 months) and chronic thromboembolic PH. For Type 4 patients, surgical treatment is preferred for patients with surgical indications, the patients with PH after surgery, patients without surgical
indications, and nonoperable cases will undergo stabilization with anticoagulant 
drugs (such as warfarin) for at least 1 month prior to study participation.

3. Age between 15–70 years, male or female.

4. WHO PAH functional classification II, IV, or V.

5. 6MWD of >100 m and <450 m at baseline.

6. Patients stable for at least 1 month after standard treatment, and patients who have 
not received treatment with interventional or surgical closure in the 6 months prior 
to participation.

7. Patient or his/her guardian agrees to participation of the patient in the study and 
provides written informed consent for participation.

**Exclusion criteria**

1. Absent or limited legal capacity.

2. Pregnant or lactating women.

3. Serious primary diseases in major organs.

4. Mental or physical disability preventing the completion of 6MWD.

5. Suspected or confirmed history of alcohol or substance abuse.

6. Known allergy to the components of TMP.

7. AST and ALT values more than three times the upper limit of normal, or Creatinine 
Clearance Rate <50 ml/min.

8. Low systemic blood pressure (<90/50 mmHg) or uncontrolled hypertension (blood 
pressure >170/110 mmHg).

9. Prior use of the study drug and discontinuation or change in targeted drugs (e.g. 
endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and guanylate 
cyclase) in the 3 months prior to screening.

10. Presence of an active infectious disease such as hepatitis A, hepatitis B, AIDS,
tuberculosis, or connective tissue diseases.

11. Presence of serious infection, especially pulmonary infections.

12. Shock or other hemodynamically unstable conditions.

13. Cirrhosis or portal hypertension caused by cirrhosis.

14. Severe bleeding or bleeding tendency such as active peptic ulcer, intracranial hemorrhage, trauma, or other bleeding events.

15. Acute or chronic organic diseases (except for dyspnea) or other conditions (such as limb diseases) that may result in the subject being unable to complete the study (especially the 6MWD).

16. Use or accidental use of foods or drugs that may impact test results during the treatment period (e.g., amirace, fenfluramine, dexfenfluramine, L-tryptophan, methamphetamine, and phenylflurazone).

17. Any other circumstances under which the investigator considers the patient to be unsuitable for participation in the study.

**Withdrawal criteria**

1. Subjects having poor compliance with the dosing regimen.

2. Use or accidental use of foods or drugs that may impact test results during the treatment period (e.g., amirace, fenfluramine, dexfenfluramine, L-tryptophan, methamphetamine, and phenylflurazone).

3. Subjects with incomplete key data that may affect the statistical analysis.

**Endpoint standards**

1. Subjects experiencing serious adverse reactions leading to suspension or termination of treatment during the study.

2. Subjects whose condition deteriorates during the study.

3. Subjects who withdraw consent or are unable to complete the study because of other
circumstances.

4. Patients treated with targeted drugs for Type 1 or Type 4 PH prior to testing who stopped treatment with the targeted drug for any reason during the study and did not reinitiate treatment.

5. Death (from PH or another cause).

**Interventions**

Subjects satisfying all criteria will be assigned (2:1) randomly into two groups as follows:

1. **TMP treatment group:** TMP 100 mg 3 times daily in addition to routine therapy.

2. **Control group:** routine therapy only.

The routine therapy is followed by 2015 ESC Guideline. The current treatment strategy for PAH patients can be divided into three main steps:

(1) The initial approach includes general measures (physical activity and supervised rehabilitation, pregnancy, birth control and post-menopausal hormonal therapy, elective surgery, infection prevention, psychosocial support, adherence to treatments, genetic counselling and travel), supportive therapy (oral anticoagulants, diuretics, O₂, digoxin), referral to expert centers and acute vasoreactivity testing for the indication of chronic CCB therapy.

(2) The second step includes initial therapy with high-dose CCB in vasoreactive patients or drugs approved for PAH in non-vasoreactive patients according to the prognostic risk of the patient and the grade of recommendation and level of evidence for each individual compound or combination of compounds.

(3) The third part is related to the response to the initial treatment strategy; in case of an inadequate response, the role of combinations of approved drugs and lung transplantation are proposed.

It is important to monitor renal function and blood biochemistry in patients with diuretic
use to avoid hypokalaemia and the effects of decreased intravascular volume leading to pre-renal failure.

Optimal medical treatment for CTEPH consists of anticoagulants and diuretics, and $O_2$ in cases of heart failure or hypoxaemia.

TMP was produced by Livzon Pharmaceutical Group Inc. (Zhuhai, Guangdong Province, China), following the instructions of the People’s Republic of China Pharmacopoeia [22]. Routine therapy will not differ between the two groups, and will include phosphodiesterase type 5 inhibitors (sildenafil and tadalafil). Where subjects have previously received targeted drugs for the treatment of PH, the regimen will remain unchanged.

**Outcome measurements**

**Efficacy indicators**

The main efficacy indicators are 6MWD and heart rate recovery at 1 minute after the 6MWD (Table 2).

Secondary efficacy measurements include the following 12 indicators (Table 2): PH WHO Classification, Borg Dyspnea Score, Minnesota Living with Heart Failure Questionnaire, N-terminal pro-brain natriuretic peptide, cardiac troponin I, right ventricular systolic pressure evaluated by echocardiogram, uric acid, volume of pericardial effusion, pulmonary artery diameter assessed by CT, diameter of the same layer of aorta assessed by CT, arterial oxygen saturation, and time of clinical deterioration.

**Safety evaluation**

Symptoms and signs including respiration rate, heart rate, and blood pressure will be recorded at each visit. Laboratory tests will be performed within 3 days prior to enrollment, and will include routine blood tests and urinalysis, liver function, renal function, coagulation function, NT-proBNP and electrocardiography. Adverse events will be assessed and recorded in the case report form.
**Evaluation of adverse events**

Adverse events, including symptoms, signs, and physical or laboratory examination abnormalities, will be carefully evaluated. All adverse events must be judged for their character, severity, and potential relationship to the study treatment. The correlation between adverse events and study treatment is divided into five levels: definite, probable, possible, unrelated.

**Treatment allocation**

As the study is single-blind, only the participant will be unaware of which treatment they receive; those responsible for their care and evaluation (treating team and research team) will know the allocation or coding of the treatment allocation. This blinding of the participant will be achieved by identical packaging and labelling of both the TMP tablet and matched placebo. Each container of TMP/placebo will be identified by a unique kit code. Randomized lists containing kit allocation will be computer-generated by the safety statistician and sent to the research investigator who will produce the kits and allocation sequence. The safety statistician will manage the kit codes in the kit logistics application, which is linked to the 24-h randomization system, and will maintain the back-up kit-code lists for each site.

**Data Management and analysis**

**General considerations**

Per protocol set will pick up from the full analysis set for analysis. Statistical analysis of the efficacy of the study will be performed using statistical data sets that met the protocol. The data will be analyzed by two-sided t test, with categorical variables analyzed by χ² test and rank variables by paired Wilcoxon rank sum test. The test level α is 0.05, and P values ≤0.05 will be considered statistically significant.

The methods that will be used to handle missing data are described for each analysis. As
this is a single-blind study, the study statistician will be blinded to treatment group allocation throughout the study until the database has been locked and downloaded for final analysis. Only the safety statistician, supervising study statistician, back-up safety statistician, and authorized individuals will have access to the treatment group allocations prior to the final analysis.

**Frequency of analyses**

Outcome data will be analyzed for one time only at the final analysis, although statistical monitoring of safety data will be conducted throughout the study and reported at agreed intervals. Final analysis will take place 16 weeks after the last patient is randomized.

**Endpoint analysis**

All analyses will be conducted using data from the intention-to-treat population, defined as all patients who undergo randomization regardless of non-compliance with the intervention. The primary endpoint will be analyzed in the per-protocol population to determine whether the results are sensitive to the exclusion of patients who violated the protocol (e.g. those patients who underwent randomization but were subsequently found to be ineligible). Primary and secondary analyses will be performed by an investigator who is unblinded to treatment allocation. Outcome measures will be analyzed by $\chi^2$ test and rank variables by paired Wilcoxon rank sum test appropriate for the data type. Such analyses will be adjusted for randomization minimization factors such as baseline values where applicable (such as age and sex). Baseline characteristics will be summarized for each randomized group.

**Safety analyses**

All patients who receive at least one dose of trial treatment will be included in the safety analysis set. The number of patients reporting a serious adverse event (up to 28 days after the last dose of treatment) and the details of all serious adverse events will be
reported for each treatment group. The number of patients withdrawing from treatment will be summarized by treatment arm, along with the reasons for withdrawal. All safety analyses performed prior to final analysis will be undertaken by the safety statistician.

**Subgroup analyses**

No subgroup analyses are planned.

**Adverse events**

An adverse event is defined as any untoward medical occurrence (including deterioration of a pre-existing medical condition) in a patient who has been administered a medicinal product; the event does not necessarily have a causal relationship with this product. The occurrence of adverse events will be recorded at Visits 1–4. At each visit, the research nurse will complete the adverse event checklist to determine whether the patient has experienced any of the expected adverse events. Only the occurrence and corresponding severity of adverse events will be recorded.

**Ethics**

The present study is being conducted in accordance with the Declaration of Helsinki and relevant clinical study research regulations in China. The protocol was approved by the Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University. Prior to participation, all subjects must provide written informed consent.

**Discussion**

To date, many targeted drugs have emerged for the treatment of PH, however, these drugs are limited by the unsatisfactory long-term efficacy and their expensive price. Ligustrazine is an alkaloid extracted from Traditional Chinese Medicine Herb Ligusticum wallichii Franch (ie., Ligusticum chuanxiong Hort). TMP has a variety of cardio-cerebral vascular pharmacological effects such as protection of vascular endothelium, antiplatelet, anti-ischemia reperfusion injury, antioxidative stress, etc.. [22]Moreover, TMP has been
widely used in China clinics for the treatment of occlusive cardiovascular and cerebrovascular diseases such as coronary heart disease, cerebral thrombosis and vasculitis. [22] Besides, TMP has also been reported for the treatment of various diseases such as cor pulmonale, heart disease, kidney disease, portal hypertension, type 2 diabetes, tumor and restenosis after coronary stenting in recent years. [23-29] At present, TMP phosphate tablets are one of the most commonly used drugs in clinical practice in China. Some basic researches have shown that treatment with TMP decreased the hypoxia-induced rat pulmonary microvascular endothelial cells monolayer permeability that it can be used to treat pulmonary hypertension. [30, 31] However, there is little evidence to date of the efficacy and safety of TMP therapy for PH. We conducted a literature search on the side effects of TMP, all the current reported side effects are from injections, including phlebitis, chills, fever, rash, itching, chest tightness, palpitations, dizziness, dyspnea, sore throat and so on. [32, 33] We found that no report has yet evaluated the adverse events associated with oral TMP treatment, and there is also no access to information from the website National Center for ADR, China (http://www.cdr-adr.org.cn/). Besides, the clinical observation of our own hospital has confirmed that the oral intake of TMP is safe, without obvious adverse reactions. Thus, the present clinical study is expected to provide evidence for the safety and efficacy of TMP, a new affordable potential treatment for PH.

There are some limitations in this clinical study. Due to its odour, we set the study as a single-blinded clinical study. Besides, the scale of this clinical study is relatively small. We plan to conduct a large-scale clinical study subsequently to comprehensively evaluate the efficacy and safety of TMP in the treatment of PH, based on the findings of the present study.

**Trial status**
Recruitment started in September 2018 and is planned to end in October 2018, with 120 patients randomized. Treatment with TMP is ongoing at present and is expected to finish in October 2019. The current protocol version is 2.0, dated 28 September 2018.

List Of Abbreviations

6MWD: 6-minute walk distance, WHO: World Health Organization, PH: pulmonary hypertension, TMP: tetramethylpyrazine.

Declarations

**Ethics approval and consent to participate**

This study was approved by the Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University. Prior to participation, all subjects provided written informed consent.

**Consent for publication**

Not applicable.

**Availability of data and material**

Not applicable.

**Competing interests**

As this is a clinical study initiated by researchers. The authors declare that they have no competing interests.

**Funding**

This work was supported in part by grants from the National Natural Science Foundation of China (81630001), Department of Science and Technology of China (2016YFC1304102, 2016YFC0903700), Changjiang Scholars and Innovative Research Team in University (IRT0961), Guangdong Department of Science and Technology (2017A020215114, 2016A030311020, 2016A030313606), Guangzhou Department of Education Yangcheng
Scholarship (12A001S), Guangzhou Department of Education Scholarship (1201630095), State Key Laboratory of Respiratory Disease grant (SKLRD-QN-201704), Guangzhou Department of Science and Technology (2014Y2-00167), and the Guangdong Province Universities, Colleges Pearl River Scholar Funded Scheme of China.

Authors’ contributions
JW was the coordinator of the study, and WH wrote the first draft of the manuscript. YC was critically involved as co-principal investigator in the planning and the conduct of the study (application for funding and trial design) and in finalizing the manuscript. HOY and KY were involved in critically revising the manuscript. TW helped to finalize the manuscript. CH and CL were investigators at the clinical site. WL was responsible for planning all statistical analyses. All authors read and approved the final manuscript.

Acknowledgements
None.

References
1. Lo CCW, Moosavi SM, Bubb KJ: The Regulation of Pulmonary Vascular Tone by Neuropeptides and the Implications for Pulmonary Hypertension. *Frontiers in physiology* 2018, 9:1167.
2. Bourgeois A, Omura J, Habbout K, Bonnet S, Boucherat O: Pulmonary Arterial Hypertension: New Pathophysiological Insights and Emerging Therapeutic Targets. *The international journal of biochemistry & cell biology* 2018.
3. Meyer G: Effective diagnosis and treatment of pulmonary embolism: Improving patient outcomes. *Archives of cardiovascular diseases* 2014, 107(6-7):406-414.
4. Valverde AB, Soares JM, Viana KP, Gomes B, Soares C, Souza R: Pulmonary arterial hypertension in Latin America: epidemiological data from local studies. *BMC*
5. Condon DF, Nickel NP, Anderson R, Mirza S, de Jesus Perez VA: The 6th World Symposium on Pulmonary Hypertension: what's old is new. F1000Res 2019, 8.

6. Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, Jing ZC, Gibbs JS: A global view of pulmonary hypertension. The Lancet Respiratory medicine 2016, 4(4):306-322.

7. Olsson KM, Halank M, Egenlauf B, Fistera D, Gall H, Kaehler C, Kortmann K, Kramm T, Lichtblau M, Marra AM et al: Decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol 2018.

8. Berthelot E, Bauer F, Eicher JC, Flecher E, Gellen B, Guihaire J, Guijarro D, Roul G, Salvat M, Tribouilloy C et al: Pulmonary hypertension in chronic heart failure: definitions, advances, and unanswered issues. ESC heart failure 2018.

9. Petry A, Trautz B, Kracun D, Zhang Z, Vogel F, Weitnauer M, Hochkogler K, Gorlach A: Stabilization of p22phox by hypoxia promotes pulmonary hypertension. Antioxidants & redox signaling 2018.

10. Huber LC, Leuenberger C, Kohler M, Brock M: [Pulmonary hypertension: microRNAs in pathogenesis, diagnosis and therapy]. Pneumologie (Stuttgart, Germany) 2014, 68(6):386-393.

11. Chen HP, He M, Huang QR, Zeng GH, Liu D: Delayed protection of tetramethylpyrazine on neonatal rat cardiomyocytes subjected to anoxia-reoxygenation injury. Basic Clin Pharmacol Toxicol 2007, 100(6):366-371.

12. Cao J, Miao Q, Miao S, Bi L, Zhang S, Yang Q, Zhou X, Zhang M, Xie Y, Zhang J et al: Tetramethylpyrazine (TMP) exerts antitumor effects by inducing apoptosis
and autophagy in hepatocellular carcinoma. *International immunopharmacology* 2015, **26**(1):212-220.

13. Liu X, Liu H, Zeng Z, Zhou W, Liu J, He Z: **Pharmacokinetics of ligustrazine ethosome patch in rats and anti-myocardial ischemia and anti-ischemic reperfusion injury effect.** *International journal of nanomedicine* 2011, **6**:1391-1398.

14. Tsai CC, Lai TY, Huang WC, Liu IM, Liou SS: **Role of cGMP signals in tetramethylpyrazine induced relaxation of the isolated rat aortic strip.** *Life sciences* 2005, **77**(13):1416-1424.

15. Sun MY, Zhang M, Chen SL, Zhang SP, Guo CY, Wang JS, Liu X, Miao Y, Yin HJ: **The Influence of Hyperlipidemia on Endothelial Function of FPN1 Tek-Cre Mice and the Intervention Effect of Tetramethylpyrazine.** *Cell Physiol Biochem* 2018, **47**(1):119-128.

16. Guo M, Liu Y, Shi D: **Cardiovascular Actions and Therapeutic Potential of Tetramethylpyrazine (Active Component Isolated from Rhizoma Chuanxiong): Roles and Mechanisms.** *BioMed research international* 2016, **2016**:2430329.

17. Zhao Y, Liu Y, Chen K: **Mechanisms and Clinical Application of Tetramethylpyrazine (an Interesting Natural Compound Isolated from Ligusticum Wallichii): Current Status and Perspective.** *Oxidative medicine and cellular longevity* 2016, **2016**:2124638.

18. Li H, Yang X, Shi W, Ma Z, Feng GK, Yin YL, Fan YX, Jiang J: **Protective Effects of Tetramethylpyrazine on Cerebrovascular Regulations in Rats with Chronic Alcoholic Encephalopathy.** *Biomedical and environmental sciences : BES* 2015, **28**(9):691-695.

19. Mirrakhimov AE, Strohl KP: **High-altitude Pulmonary Hypertension: an Update**
on Disease Pathogenesis and Management. *Open Cardiovasc Med J* 2016, **10**:19-27.

20. Huber LC, Bye H, Brock M: **The pathogenesis of pulmonary hypertension--an update.** *Swiss Med Wkly* 2015, **145**:w14202.

21. Qian W, Xiong X, Fang Z, Lu H, Wang Z: **Protective effect of tetramethylpyrazine on myocardial ischemia-reperfusion injury.** *Evidence-based complementary and alternative medicine : eCAM* 2014, **2014**:107501.

22. Huang YT, Chang FC, Chen KJ, CY H: **Acute hemodynamic effects of tetramethylpyrazine and tetrandrine on cirrhotic rats.** *Planta Medica* 1998, **65**:130-134.

23. Chen Z, FX Z: **Therapeutic effect of astragalus and ligustazine injection on chronic congestive heart failure.** *Medical Forum Magazine* 2011, **32(6)**(6):2.

24. Cheng SB, Lu KR, DA W: **Effect of ligustazine on pulmonary artery pressure and vascular endothelial cell function in patients with pulmonary heart disease.** *JOURNAL OF CHINESE MEDICINAL MATERIALS* 2011, **34**(1):3.

25. Dong XJ, Jiang YM, Yu LC, RB P: **Research progress of tetramethylpyrazine derivatives and their pharmacological activities.** *Central South Pharmacy* 2012, **4**(10):6.

26. Jiang YR, KY C: **Advances in pharmacological effects and clinical application of ligustrazine.** *Chinese Journal of Integrated Traditional and Western Medicine* 2013, **5**(33):5.

27. JX L: **Clinical efficacy of ligustrazine in the treatment of 60 cases of benign hypertension with nephrosclerosis complicated with renal failure.** *Chinese Journal of Modern Drug Application* 2015, **10**:2.

28. Tian CJ, Cheng CR, Xiong Y, SQ O: **Systematic evaluation of ligustrazine in the**
treatment of diabetic nephropathy. *China Pharmacy* 2012, **19**(23):6.

29. Wang KQ, Zhang FM, XZ X: **High dose ligustrazine study on the effect of PAI-1 activity level in type 2 diabetes.** *Clinical experience* 2004, **4**(20):25.

30. Mehmood K, Zhang H, Li K, Wang L, Rehman MU, Nabi F, Iqbal MK, Luo H, Shahzad M, Li J: **Effect of tetramethylpyrazine on tibial dyschondroplasia incidence, tibial angiogenesis, performance and characteristics via HIF-1α/VEGF signaling pathway in chickens.** *Scientific Reports* 2018, **8**(1).

31. Zhang L, Deng M, Zhou S: **Tetramethylpyrazine inhibits hypoxia-induced pulmonary vascular leakage in rats via the ROS-HIF-VEGF pathway.** *Pharmacology* 2011, **87**(5-6):265-273.

32. Feng JW, Cui XM, X W: **Analysis of 59 cases of adverse reactions of Danshen Ligustrazine Injection.** *Chinese Journal of Clinical Rational Drug Use* 2019, **16**:2.

33. Cao LJ, X Z: **Report of 668 cases of adverse reactions caused by Danshen Ligustrazine Injection.** *Evaluation and Analysis of Drug-Use in Hospitals of China* 2018, **12**:3.

Tables

Table 1 Study schedule of assessments
| Visit cycle evaluation projects | Screening stage | Visit 1 | Visit 2 | Visit 3 | Visit 4 |
|-------------------------------|----------------|--------|--------|--------|--------|
| Time-Window                   | Day -3-0       | Week 4 | Week 8 | Week 12| Week 16|
| Inclusion and exclusion criteria | √               |        |        |        |        |
| Informed consent              | √               |        |        |        |        |
| Basic condition               | √               |        |        |        |        |
| Basic medical history         | √               |        |        |        |        |
| Complication                  | √               | √      | √      | √      | √      |
| Symptoms and signs            | √               | √      | √      | √      | √      |
| Drug combination              | √               | √      | √      | √      | √      |
| Blood routine test, urine routine, liver and kidney function, coagulation function | √ |        |        |        |        |
| Evaluation of cardiopulmonary function (6MWD, WHO-FC, Borg Score, MLHFQ) | √ | √ |        |        |        |
| Electrocardiogram             | √               |        |        |        |        |
| Imaging                       | √               |        |        |        |        |
| Arterial blood gases          | √               |        |        |        |        |
| NT-proBNP, cTNI levels        | √               |        |        |        |        |
| Echocardiography              | √               |        |        |        |        |
| Pulmonary function test       | √               |        |        |        |        |
| Adverse events                | √               | √      | √      | √      | √      |

✓, required

Basic medical history contains current medical history (symptoms and signs) and previous history

Evaluation of cardiac and pulmonary function includes a 6-minute walk distance (6MWD), Minnesota Living with Heart Failure Questionnaire (MLHFQ), Borg Score, and World Health Organization functional class (WHO-FC)

Safety parameters include routine blood tests and urinalysis, liver and kidney function, and coagulation function.

Table 2 Efficacy indicators
| Main efficacy indicators | Secondary efficacy measurements |
|--------------------------|---------------------------------|
| 6MWD                     | Pulmonary Hypertension WHO Classification |
| HRR1                     | Borg Dyspnea Score               |
|                          | Minnesota Living with Heart Failure Questionnaire |
|                          | NT-proBNP                        |
|                          | cTNI                             |
|                          | RVSP                             |
|                          | Uric acid                        |
|                          | Volume of pericardial effusion   |
|                          | Pulmonary artery diameter        |
|                          | Diameter of the same layer of aorta |
|                          | Arterial oxygen saturation       |
|                          | Time of clinical deterioration    |

Clinical deterioration is defined as the need to increase medication or change the therapeutic regimen for the treatment of PH, particularly inhaled, intravenous, or subcutaneous application of prostacyclin and its analogues; aggravated symptoms of right heart failure that do not respond to diuretics; atrial septostomy or death; lung transplantation; or hospitalization caused by exacerbation of PH. Other clinical symptoms and signs, biochemical indicators, and imaging indicators are recorded (Table 2) for comprehensive prognostic evaluation and risk assessment.

Figures
Figure 1

Flow chart for enrollment and follow-up of participants

Supplementary Files

This is a list of supplementary files associated with the primary manuscript. Click to download.

SPIRIT_Fillable-checklist-15-Sep-2019.pdf
Equation 1.jpg
